Cvrx, Inc. Stock Price, News & Analysis

CVRx (NASDAQ: CVRX) reported third-quarter 2025 results: revenue $14.7M (+10% YoY) with U.S. revenue $13.5M (+10% YoY) and 250 active U.S. implanting centers. Gross profit was $12.8M (+15% YoY) and gross margin 87% (up from 83%). Net loss narrowed slightly to $12.9M (−$0.2M) or $0.49 per share. Cash and cash equivalents totaled $85.1M. CMS finalized Category I CPT coding, which management cites as improving patient access and reducing adoption barriers. Full‑year 2025 guidance was updated to $55.6M–$56.6M revenue, 85%–86% gross margin, and $98M–$99M operating expenses. The company expects Q4 2025 revenue of $15.0M–$16.0M.

CVRx (NASDAQ: CVRX) announced that management will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov 18, 2025.

The presentation is scheduled for 8:00 a.m. GMT / 4:00 a.m. ET and will be available live via audio webcast on the company investor relations site at ir.cvrx.com.

CVRx (NASDAQ: CVRX) will release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The company will host a conference call to review results on Nov. 5, 2025 at 4:30 p.m. Eastern Time.

A live webcast will be available at the company investor relations page (ir.cvrx.com). U.S. telephone dial-in is 1-877-704-4453; international dial-in is 1-201-389-0920. Callers are asked to dial in approximately ten minutes before the start time.

CVRx (NASDAQ: CVRX) reported its Q2 2025 financial results, achieving total revenue of $13.6 million, up 15% year-over-year. The company's U.S. Heart Failure revenue reached $12.1 million, also growing 15%. Active U.S. implanting centers increased 27% to 240 centers.

Key developments include CMS's proposal to maintain Barostim in APC 1580 for 2026 with a $45,000 outpatient procedure payment, favorable physician fee proposals for Category I CPT codes, and the appointment of Brent Binkowski as COO. The company narrowed its FY2025 guidance to $55.0-$57.0 million in revenue with 83-84% gross margin.

Despite revenue growth, CVRx reported a net loss of $14.7 million ($0.57 per share) and held $95.0 million in cash and equivalents as of June 30, 2025.

CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on Tuesday, August 12, 2025, at 3:00 PM ET.

Investors and interested parties can access the live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.

CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has scheduled its second quarter 2025 financial results announcement for August 4, 2025, after market close.

The company will host a conference call at 4:30 PM Eastern Time to discuss the results. Investors can access the call via telephone using the conference ID CVRXQ225 or through a live webcast available on the company's investor relations website at ir.cvrx.com.

[]

CVRx (NASDAQ: CVRX) announced that CMS has proposed to maintain Barostim implant procedures in the New Technology APC 1580, with an approximate payment of $45,000 for outpatient procedures. This follows two significant reimbursement developments: Barostim's assignment to a higher-paying MS-DRG for inpatient procedures (October 2024) and its transition from Category III to Category I CPT codes for physician payments (effective January 2026).

The final 2026 Medicare Hospital OPPS rule is expected in November 2025, with implementation planned for January 2026. These reimbursement updates validate Barostim's clinical value in treating heart failure patients with reduced ejection fraction.

CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The company's management team is scheduled to present on June 4, 2025, at 10:00am Central Time. Investors and interested parties can access the live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.

CVRx reported its Q1 2025 financial results with total revenue of $12.3 million, up 15% year-over-year. U.S. Heart Failure revenue reached $11.1 million, a 14% increase. The company expanded its U.S. presence to 227 active implanting centers, a 19% growth since March 31, 2024. Notable achievements include compelling real-world evidence showing Barostim's effectiveness, with an 85% reduction in heart failure hospital visits. However, financial challenges persist with a net loss of $13.8 million ($0.53 per share). The company updated its 2025 guidance, projecting total revenue between $55-58 million. CVRx maintains strong liquidity with $102.7 million in cash and cash equivalents, while continuing to invest in commercial expansion despite revenue growth not meeting expectations.